C. Thieblemont et al., PROGNOSTIC FACTORS IN CHORDOMA - ROLE OF POSTOPERATIVE RADIOTHERAPY, European journal of cancer, 31A(13-14), 1995, pp. 2255-2259
We have investigated prognostic factors for survival in a series of 26
patients with chordoma treated in Lyon, France, between 1979 and 1993
. In this series, the median progression-free (PFS) and overall surviv
al (OS) were 10 and 90 months, respectively. In univariate analysis, P
FS, but not OS, was found significantly longer in males as compared to
females (median: 19 versus 7 months, P = 0.05); and patients under 60
years of age had a longer PFS (median: 18 versus 6 months; P = 0.06)
and OS (median: 108 versus 47+, P = 0.05) than older patients. A favou
rable prognostic subgroup including male patients under 60 years and a
poor prognostic group including female patients and male over 60 year
s were thus defined (median PFS: 36 versus 6 months, P = 0.001; median
OS: 108 versus 55+, P = 0.15). Primary treatment combining surgery an
d postoperative radiotherapy was associated with a longer PFS than sur
gery only (median: 36 versus 7 months, P = 0.002) in the whole series
and in both prognostic subgroups.